Cancer Diagnostics and Genomic Health

Selected news for the healthcare topic - Cancer Diagnostics, and the company - Genomic Health. We have 63 shared news items for this connection to-date.

Please provide a valid email address.

Selected Headlines

Date Headline (link) Source Relevant Snippet
9/16/2021 Outlook on the Breast Cancer Diagnostics Global Market to 2028 - by Product, Type, Application, End-use and Region Yahoo News DUBLIN , Sept. 16, 2021 /PRNewswire/ -- The "Global Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report by Product (Platform-based, Instrument-based), by Type (Imaging, Biopsy, Genomic Tests, Blood Tests), by Application, by End-use ... In November 2019 , Exact Sciences Corporation announced the acquisition of Genomic Health, which was expected to help enhance the company's market position and offerings by acquiring its product portfolio. In January 2021 , Hologic Inc. announced ...
9/16/2021 Global Breast Cancer Diagnostics Market (2021 to 2028) - Size, Share & Trends Analysis Report Globe Newswire Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report by Product (Platform-based, Instrument-based), by Type (Imaging, Biopsy, Genomic Tests, Blood Tests), by Application, by End-use, by Region, and Segment Forecasts, 2021-2028" +-+Size ... In November 2019, Exact Sciences Corporation announced the acquisition of Genomic Health, which was expected to help enhance the company's market position and offerings by acquiring its product portfolio. In January 2021, Hologic Inc. announced ...
9/15/2021 Worldwide Breast Cancer Diagnostics Industry to 2028 ‚Äì Featuring Koninklijke Philips, Danaher and Hologic Among Others ‚Äì ResearchAndMarkets.com ... Genomic Health, which was expected to help enhance the company‚Aos market position and offerings by acquiring its product portfolio. In January 2021, Hologic Inc. announced that it has agreed to acquire Biotheranostics for approximately US$ 230 million. Biotheranostics is a commercial-stage molecular diagnostics provider for breast and metastatic cancers.Breast Cancer Diagnostics Market Report Highlights The imaging segment held the largest revenue share in 2020 and the blood ...
9/15/2021 Worldwide Breast Cancer Diagnostics Industry to 2028 - Featuring Koninklijke Philips, Danaher and Hologic Among Others - ResearchAndMarkets.com | Business Wire Business Wire DUBLIN--( BUSINESS WIRE )--The "Global Breast Cancer Diagnostics Market Size, Share & Trends Analysis Report by Product (Platform-based, Instrument-based), by Type (Imaging, Biopsy, Genomic Tests, Blood Tests), by Application, by End-use, by Region ... Inc Becton, Dickinson and Company Qiagen Thermo Fisher Scientific, Inc. Genomic Health (Exact Sciences) Myriad Genetics, Inc. Argon Medical Devices Inc. F. Hoffmann-La Roche Ltd The introduction of 3D mammography or digital breast tomosynthesis ...
9/7/2021 Breast Cancer Diagnostics Market Size, Growth, Opportunity and Forecast to 2026 The Breast Cancer Diagnostics Market dynamics, forces, companies and trends have been determined after conducting a detailed study of the industry for this newly released research report now available with Market Study Report. Global Breast ... Inc. Toshiba Corporation Aurora Imaging Technology Inc. Dilion Technologies Inc. Genomic Health NanoString Technologies, Inc. Request a sample of this premium report at: https://www.marketstudyreport.com/request-a-sample/2610785/?utmsource=Marketwatch.com&utmmedium=SK ...
7/21/2021 Prostate Cancer Diagnostics Market Size Soaring at 7% CAGR to Reach 15640 million USD by 2025 Selbyville, Delaware Market Study Report LLC has added a new report on Prostate Cancer Diagnostics market that provides a comprehensive review of this industry with respect to the driving forces influencing the market size. Comprising ... innovations. The major players covered in Prostate Cancer Diagnostics are: Genomic Health, MDx Health, Siemens Healthcare, Abbott, Roche, OPKO, Myriad Genetics, BioMeriux, DiaSorin, Beckman Coulter, Ambry Genetics, etc. Market segmentation Prostate Cancer Diagnostics market is ...
7/17/2021 Rapid Expansion Projected for Prostate Cancer Diagnostics MarkeÔªø‚Äãt Forecast Till 2026 The ‚AoGlobal Prostate Cancer Diagnostics Market Analysis to 2026‚Ao is a specialized and in-depth study of the industry with a special focus on the global market trend analysis. The report aims to provide ... of Global Report: https://www.researchreportsinc.com/report-sample/122751 Market Player: Genomic Health Abbott OPKO Siemens Healthcare DiaSorin BioMeriux Roche MDx Health Beckman Coulter Myriad Genetics Ambry Genetics Market Segmentation by Type: Tumor Biomarker Tests Imaging ...
4/19/2021 Prostate Cancer Diagnostics Market going to reach usd millions By the end of 2025 :Siemens Healthcare, DiaSorin, bioMeriux Prostate Cancer Diagnostics‚Au Latest Research Report: Prostate Cancer Diagnostics industryThe prostate is a walnut-sized gland located behind the base of a man‚Aos penis, in front of the rectum, and below the ... Prostate Cancer Diagnostics Market competition by top manufacturers as follow: , Genomic Health, Abbott, OPKO, Siemens Healthcare, DiaSorin, bioMeriux, Roche, MDx Health, Beckman Coulter, Myriad Genetics, Ambry Genetics,The rising technology in Prostate Cancer Diagnostics market ...
3/29/2021 Global Breast Cancer Diagnostics Market (Covid 19 Update) Competitive Insights, Trends and Demand Growth 2020 to 2027 March 29, 2021Breast cancer diagnostics the market to account to USD 36.5 billion by 2027 growing at a CAGR of 6.70% in the above-mentioned forecast period. Increasing awareness among the people regarding the ... players covered in the breast cancer diagnostics market report are Genomic Health., Myriad Genetics, Inc., NanoString Technologies, Inc., Hologic, Inc., Koninklijke Philips N.V., Danaher, BD, Devicor Medical Products, Inc., Paragon Biosciences LLC, Todos Medical, BioNTech ...
3/4/2021 Global Prostate Cancer Diagnostics Market is expected to grow with the CAGR of 20.1% in the forecast period of 2021 to 2028. The years considered for study are as mentioned below. | Data Bridge Market Reseach Global Prostate Cancer Diagnostics 20.1% in the forecast period of 2021 to 2028. The years considered for study are as //www.databridgemarketresearch.com/reports/global-prostate-cancer-diagnostics-marketGlobal prostate cancer diagnostics market, which includes specific ... Inc., DiaSorin S.p.A, Beckman Coulter, Inc. (a subsidiary of Danaher), Genomic Health, Inc. (a subsidiary of Exact Sciences Corporation), bioMérieux SA, Metamark Genetics, Inc., Prostatype Genomics, Fujirebio, Proteomedix, Eurolyser Diagnostica GmbH among others domestic ...
10/6/2020 Global Prostate Cancer Diagnostics Market Growth 2020-2025 Global Prostate Cancer Diagnostics Market Growth 2020-2025 Published: Single User License: US $ 3660 Corporate User License: US $ 7320 Table of Contents According to this study, over the next five years the Prostate Cancer Diagnostics market ... covered in this report: Breakdown data in in Chapter 3. - Genomic Health - Roche - Ambry Genetics In addition, this report discusses the key drivers influencing market growth, opportunities, the challenges and the risks faced by key ...
6/15/2020 At 7 % CAGR, Prostate Cancer Diagnostics Market Size Set to Register 15640 million USD by 2025 Selbyville, Delaware According to Market Study Report LLC has added a new report on Prostate Cancer Diagnostics market that provides a comprehensive review of this industry with respect to the driving forces influencing the market ... AG The major players covered in Prostate Cancer Diagnostics are: Genomic Health, MDx Health, Siemens Healthcare, Abbott, Roche, OPKO, Myriad Genetics, BioMeriux, DiaSorin, Beckman Coulter, Ambry Genetics, etc. The Prostate Cancer Diagnostics market report provides ...
4/17/2020 Genomics Industry Review 2015-2019 and Opportunity Outlook 2020-2030 PR Newswire ... competitive edge over their rivals. For instance, in 2018, NanoString Technologies, Inc., a USA -based biotech company, specialized in developing cancer diagnostics tools launched a CAR-T characterization panel, a new gene expression panel for ... screening for early detection and prevention of colorectal cancer, acquired Genomic Health Inc. for $2.8 billion in cash. The acquisition is expected to help Exact Sciences Corp. to broaden its offering of cancer tests and ...
4/13/2020 Key Players in The $852 Million Genomics Market At Investing in New Product Launches PR Newswire ... competitive edge over their rivals. For instance, in 2018, NanoString Technologies, Inc., a USA -based biotech company specialized in developing cancer diagnostics tools, launched a CAR-T characterization panel, which is a new gene expression ... 2020-covid-19-implications-and-growth Exact Sciences Corp. Acquires Genomic Health Inc. Other players in the market are investing in mergers and acquisitions as part of their growth strategies. Exact Sciences Corp. is a ...
11/19/2019 Is Exact Sciences Stock a Buy? Exact Sciences just completed its multibillion-dollar acquisition of Genomic Health, setting the stage for the company’s future. (TMFHaen) Nov 19, 2019 at 11:28AM This month, Exact Sciences ( NASDAQ:EXAS ) finalized its purchase of Genomic Health, creating a formidable player in the realm of cancer diagnostics. Exact shelled out approximately $1.06 billion in cash and issued roughly 17.4 million shares to Genomic Health shareholders. Currently valued at just over $12 ...
11/19/2019 M&A Report: Exact Sciences, Roku and Anheuser-Busch In the News ... Sciences Corp. , a leading provider of cancer screening and diagnostic tests and owner of Cologuard , has completed the acquisition of Genomic Health, Inc. The acquisition is valued at $2.8 billion. Genomic Health is a leading ... combination of the two strongest and fastest growing brands in cancer diagnostics, Exact Sciences is well positioned to become a leading global cancer diagnostics company. Roku Acquires Key DSP Roku has completed the acquisition of ...
11/12/2019 BizTimes Milwaukee: Exact Sciences Corp. completes $2.8 billion acquisition by Tech Council Nov 12, 2019 NEWSROOM , Tech Council News Madison-based cancer diagnostics company Exact Sciences Corp. completed its $2.8 billion cash-and-stock deal with Redwood City, California-based Genomic Health , the company announced. Exact Sciences produces Cologuard, a noninvasive, at-home screening test that detects the presence of colon cancer in stool samples. Genomic Health develops Oncotype IQ, a portfolio of genomic tests and services that check ...
11/11/2019 Exact Sciences completes acquisition of Genomic Health for $2.8bn Molecular diagnostics firm Exact Sciences has closed its approximately $2.8bn acquisition of genomic diagnostics maker Genomic Health. In July, Exact Sciences signed a definitive agreement to acquire genomic diagnostics maker Genomic Health in a cash-and-stock deal. Exact Sciences chairman and CEO Kevin Conroy said: “We’re excited to bring together some of the greatest minds in cancer diagnostics and continue to deliver advanced tests to providers and patients along ...
11/11/2019 Exact Sciences Corp. completes $2.8 billion acquisition Read the full story from BizTimes here. Madison-based cancer diagnostics company Exact Sciences Corp. completed its $2.8 billion cash-and-stock deal with Redwood City, California-based Genomic Health , the company announced. Exact Sciences produces Cologuard, a noninvasive, at-home screening test that detects the presence of colon cancer in stool samples. Genomic Health develops Oncotype IQ, a portfolio of genomic tests and services that check for various cancers ...
11/8/2019 Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company – Company Announcement - FT.com Financial Times Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth MADISON, Wis. , Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp . (NASDAQ: EXAS) today announced that it has completed its previously announced combination with Genomic Health , Inc. (NASDAQ: GHDX). "Today marks a pivotal step toward building the world's leading advanced cancer diagnostics company," said Kevin Conroy , chairman and CEO of Exact Sciences ...
11/8/2019 Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company – Company Announcement - FT.com Financial Times Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth MADISON, Wis. , Nov. 8, 2019 /CNW/ -- Exact Sciences Corp . (NASDAQ: EXAS) today announced that it has completed its previously announced combination with Genomic Health , Inc. (NASDAQ: GHDX). "Today marks a pivotal step toward building the world's leading advanced cancer diagnostics company," said Kevin Conroy , chairman and CEO of Exact Sciences ...
11/8/2019 Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company | Markets Insider Business Insider Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth MADISON, Wis. , Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced combination with Genomic Health, Inc. (NASDAQ: GHDX). "Today marks a pivotal step toward building the world's leading advanced cancer diagnostics company," said Kevin Conroy , chairman and CEO of Exact Sciences ...
11/8/2019 Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company | Markets Insider Business Insider Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth MADISON, Wis. , Nov. 8, 2019 /CNW/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced combination with Genomic Health, Inc. (NASDAQ: GHDX). "Today marks a pivotal step toward building the world's leading advanced cancer diagnostics company," said Kevin Conroy , chairman and CEO of Exact Sciences ...
11/8/2019 Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company | Markets Insider Business Insider Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth MADISON, Wisconsin , Nov. 8, 2019 /PRNewswire/ -- Exact Sciences Corp. (NASDAQ: EXAS) today announced that it has completed its previously announced combination with Genomic Health, Inc. (NASDAQ: GHDX). "Today marks a pivotal step toward building the world's leading advanced cancer diagnostics company," said Kevin Conroy , chairman and CEO of Exact Sciences ...
11/8/2019 Exact Sciences Completes Combination with Genomic Health, Creating Leading Global Cancer Diagnostics Company PR Newswire Combined company joins two leading brands in cancer diagnostics, Cologuard® and Oncotype DX®, providing a strong platform for continued growth MADISON, Wis. Exact Sciences Corp. (NASDAQ: EXAS ) today announced that it has completed its previously announced combination with Genomic Health , Inc. (NASDAQ: GHDX ). "Today marks a pivotal step toward building the world's leading advanced cancer diagnostics company," said Kevin Conroy , chairman and CEO of Exact Sciences. "We're excited to bring ...